NUWE logoNUWE
Nuwellis Inc

27,338
Loading...
Loading...
News
all
press releases
Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant
The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.
Stocktwits·2mo ago
News Placeholder
More News
News Placeholder
Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago
News Placeholder
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat
Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.
Stocktwits·10mo ago
News Placeholder
Why Nuwellis Stock Is Climbing
Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting. read...
Benzinga·1y ago
News Placeholder
Nuwellis Achieves First QUELIMMUNE Sale, Cautions Investors
Nuwellis (NUWE) has provided an update. Nuwellis, Inc. has marked a significant milestone with its inaugural commercial sale of QUELIMMUNE Therapy...
TipRanks Financial Blog·1y ago
News Placeholder
DaVita, Nuwellis Extend Pilot Collaboration for Aquadex
DaVita (NYSE: DVA) recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis (NASDAQ: NUWE) until Aug 31, 2024.At the conclusion of the pilot phase...
Benzinga·1y ago
News Placeholder
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial...
Globe Newswire·2y ago
News Placeholder
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital AccountsMINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq...
Globe Newswire·2y ago
News Placeholder
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it...
Globe Newswire·2y ago

Latest NUWE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.